Volpert O V, Tolsma S S, Pellerin S, Feige J J, Chen H, Mosher D F, Bouck N
Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, IL, USA.
Biochem Biophys Res Commun. 1995 Dec 5;217(1):326-32. doi: 10.1006/bbrc.1995.2780.
To assess the ability of proteins of the thrombospondin family to inhibit angiogenesis, recombinant murine thrombospondin-2, bovine thrombospondin-2/CISP and thrombospondin-5/COMP were purified and tested for ability to block the migration of capillary endothelial cells towards a variety of inducers and to inhibit neovascularization induced in the rat cornea. Both preparations of thrombospondin-2 were active inhibitors in vitro and in vivo whereas thrombospondin-5/COMP was inactive. These results define thrombospondin-2 as a newly identified naturally occurring inhibitor of angiogenesis and suggest that the properdin-like type 1 modules that it shares with antiangiogenic thrombospondin-1 and are missing in thrombospondin-5/COMP could contribute to this activity.
为评估血小板反应蛋白家族蛋白抑制血管生成的能力，对重组鼠血小板反应蛋白-2、牛血小板反应蛋白-2/CISP和血小板反应蛋白-5/COMP进行了纯化，并测试了它们阻断毛细血管内皮细胞向多种诱导剂迁移以及抑制大鼠角膜新生血管形成的能力。两种血小板反应蛋白-2制剂在体外和体内均为活性抑制剂，而血小板反应蛋白-5/COMP则无活性。这些结果将血小板反应蛋白-2定义为一种新发现的天然血管生成抑制剂，并表明它与抗血管生成的血小板反应蛋白-1共有的、而血小板反应蛋白-5/COMP中缺失的备解素样1型模块可能促成了这种活性。
